- ASSISTANT PROFESSOR Radiation Oncology
- Rahul Parikh, MD, is a Radiation Oncologist at Mount Sinai Health System and an Attending Physician at Mount Sinai Roosevelt. He specializes in the treatment of Lymphoma/Hematologic Malignancies and Brain tumors – benign & malignant. He works closely with a multidisciplinary team of highly skilled surgeons and medical oncologists to determine the best treatment options for his patients. Dr. Parikh joined the department after completing his residency training in Radiation Oncology at UMDNJ-Robert Wood Johnson Medical School / The Cancer Institute of New Jersey where he held the title of Chief Resident Physician. He also completed his internship in preliminary internal medicine at UMDNJ. He received his medical degree from Albany Medical College in Albany, New York where he graduated with a distinction in research. His undergraduate education was received at Rensselaer Polytechnic Institute where he was graduated Magna Cum Laude from an accelerated physician-scientist (BS/MD) program. Among his many accomplishments, Dr. Parikh has authored numerous abstracts and manuscripts, has received a number of research awards, and has guest lectured at several national and international meetings. He is a member of several professional organizations, including the American Society of Therapeutic Radiology & Radiation Oncology (ASTRO), American Society of Clinical Oncology (ASCO), and Radiologic Society of North America (RSNA). His clinical research interests focus on the integration of patient reported outcomes to improve cancer care delivery and the health-related quality of life in cancer patients. Also, his interests are to optimize the use of image-guided radiation therapy (IGRT), intensity-modulated radiation therapy (IMRT), stereotactic radiotherapy (SRT), and stereotactic radiosurgery (SRS) in the management of his cancer patients. Dr. Parikh also specializes in the use of Proton Beam Therapy to treat tumors that are difficult to treat with traditional forms of radiation. He, along with other radiation oncologists from the New York Proton Consortium, treats select patients with proton beam therapy at our dedicated Proton Therapy site. He works in close collaboration with his colleagues in the radiation oncology department and throughout the cancer center to identify patients who might benefit from proton therapy. He strives to provide state-of the-art treatment while working closely with his patients to provide quality care.
Parikh RR, Moskowitz BK, Maher E, Della Rocca D, Della Rocca R, Culliney B, Shapira I, Grossbard ML, Harrison LB, Hu K. Long-term outcomes and patterns of failure in orbital lymphoma treated with primary radiotherapy. Leukemia & lymphoma 2015 Jan;.
Khan AJ, Parikh RR, Neboori HJ, Goyal S, Haffty BG, Moran MS. The relative benefits of tamoxifen in older women with T1 early-stage breast cancer treated with breast-conserving surgery and radiation therapy. The breast journal; 19(5).
Parikh RR, Haffty BG, Lannin D, Moran MS. Ductal carcinoma in situ with microinvasion: prognostic implications, long-term outcomes, and role of axillary evaluation. International journal of radiation oncology, biology, physics 2012 Jan; 82(1).
Parikh RR, Haffty BG. Local therapy matters. Oncology (Williston Park, N.Y.) 2009 Jul; 23(8).
Goyal S, Parikh RR, Green C, Schiff D, Moran MS, Yang Q, Haffty BG. Clinicopathologic significance of excision repair cross-complementation 1 expression in patients treated with breast-conserving surgery and radiation therapy. International journal of radiation oncology, biology, physics 2010 Mar; 76(3).
Parikh RR, Housman D, Yang Q, Toppmeyer D, Wilson LD, Haffty BG. Prognostic value of triple-negative phenotype at the time of locally recurrent, conservatively treated breast cancer. International journal of radiation oncology, biology, physics 2008 Nov; 72(4).
Parikh RR, Yang Q, Higgins SA, Haffty BG. Outcomes in young women with breast cancer of triple-negative phenotype: the prognostic significance of CK19 expression. International journal of radiation oncology, biology, physics 2008 Jan; 70(1).
Parikh RR, Yang Q, Haffty BG. Prognostic significance of vascular endothelial growth factor protein levels in T1-2 N0 laryngeal cancer treated with primary radiation therapy. Cancer 2007 Feb; 109(3).
Parikh RR, Gildener-Leapman N, Narendran A, Lin HY, Lemanski N, Bennett JA, Jacobson HI, Andersen TT. Prevention of N-methyl-N-nitrosourea-induced breast cancer by alpha-fetoprotein (AFP)-derived peptide, a peptide derived from the active site of AFP. Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Dec; 11(23).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Parikh did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Roosevelt Hospital - 10th Floor Lower Level
1000 10th Avenue
New York, NY 10019